New landmark trial in glaucoma co-authored by Mr Lascaratos is published in The Lancet. The United Kingdom Glaucoma Treatment Study (UKGTS) is the first randomised, triple-masked, placebo-controlled trial to assess the benefit of topical medical treatment (eye drops) for reduction of loss of vision in patients with open angle glaucoma. Our findings provide strong evidence for the vision-preserving benefit of lowering of intraocular pressure, supporting evidence from previous randomised trials that were not masked or placebo controlled. The study also provides evidence of the vision preserving benefits of topical prostaglandin analogues. Congratulations to Prof David Garway-Heath for leading this landmark study in glaucoma the results of which are likely to influence clinical decision making in this field for many years to come.